Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab in Early Axial Spondyloarthritis
NCT00235105Phase 3Unknown
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Mar 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial comparing Adalimumab with Placebo (2 arms). Primary endpoint: Assessment of SpondyloArthritis international Society 40% Response at 12 weeks. Status: unknown.
02
Drugs
Beyond the preview
Go deeper on NCT00235105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00235105.